Oncology Central

Tamoxifen as the first successful targeted therapy in cancer: the gift that kept on giving


This retrospective was triggered by the American Society for Clinical Oncology (ASCO) choosing to identify ‘50 Oncology Luminaries’ as part of the celebration for the 50th Anniversary of the Founding of ASCO [1]. The discoveries that my Tamoxifen Teams contributed over the decades to advance patient care were previously recognized by ASCO with two major awards: the American Cancer Society Award for Chemoprevention (2006) and their highest award, the David A Karnofsky Award and Medal (2008). The current recognition by ASCO prompted Commissioning Editor Ruth Williamson to ask me to “tell the story.”

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.